Headquartered in San Diego, CA·Fiscal year ends December·NASDAQ: FATE·fatetherapeutics.com
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for autoimmune disease and cancer. The therapies are derived from induced pluripotent stem cells (iPSCs). Its proprietary platform combines multiplexed engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. These lines serve as a uniform, renewable starting source for manufacturing CAR T-cell and NK cell product candidates that can be stored in inventory and produced at low cost of goods. The platform is supported by over 500 issued patents and 500 pending patent applications.
The pipeline includes:
- **FT819:** A CD19-targeting CAR T-cell candidate with a CAR inserted into the TRAC locus. It is in the potentially registrational Phase 2 RECLAIM-LN trial in lupus nephritis, which uses less-intensive, fludarabine-free conditioning. It is also in a Phase 1 autoimmune basket trial covering systemic lupus erythematosus and systemic sclerosis.
- **FT839:** A 13-edit dual CD19/CD38 CAR T-cell candidate in the Phase 1/2 COMPLETE autoimmune basket trial, which does not require conditioning chemotherapy.
- **FT836:** A MICA/B-targeting CAR T-cell candidate in a Phase 1 solid tumor basket study and a multiple myeloma investigator-initiated trial.
FT836 and FT839 incorporate the company's Sword & Shield technology, which is designed to avoid host alloreactive immune rejection. The company has no current product revenue. It is funded by its cash and investments, CIRM grants, and a collaboration with Ono. It recently added a commercial leadership role in preparation for potential commercialization. Updated
Tuesday's top analyst upgrades and downgrades included American International Group, APA, Etsy, Goldman Sachs, Howmet Aerospace, Morgan Stanley, Wayfair, Welltower, Wendy’s and Workday .
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Cheniere Energy, Chewy, Costco Wholesale, CrowdStrike, Exact Sciences, Lululemon Athletica, New York Community Bancorp, Okta, Physicians Realty Trust, Spotify Technology and Welltower.
Friday’s additional top analyst upgrades and downgrades were on BankUnited, Canadian National Railway, Fate Therapeutics, Moody's, Regions Financial, Snowflake, Travelers, Voya Financial and more.
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Analog Devices, Applied Materials, Comcast, Chipotle Mexican Grill, Grab, IBM, Johnson & Johnson, Lyft, Oracle, Roku and Snap.
Thursday's top analyst upgrades and downgrades included Dick’s Sporting Goods, Fate Therapeutics, Kimberly-Clark, Nordstrom, Roblox, TJX Companies and Zoom Video Communications.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Alexion Pharma, Activision Blizzard, Baker Hughes, BioMarin, and more.
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Ciena, CommVault Systems, Dollar General, JD.com, Kroger, Nucor, Target and Walmart.
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for autoimmune disease and cancer. The therapies are derived from induced pluripotent stem cells (iPSCs).
What is the FATE stock price target?
The Wall Street consensus 12-month price target for FATE is $5.72.